Proactive compared with passive adverse event recognition: Calcium channel blocker-associated edema

Journal of Clinical Hypertension

Volumn 10, Issue 9, 2008, Pages 716-722

  Chrysant, Steven G ^a,b  

^a UNIVERSITY OF OKLAHOMA   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; AMLODIPINE BESYLATE; AMLODIPINE PLUS OLMESARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CLONIDINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FELODIPINE; HYDROCHLOROTHIAZIDE; ISRADIPINE; LACIDIPINE; LERCANIDIPINE; NICARDIPINE; NIFEDIPINE; NISOLDIPINE; PLACEBO; PRAZOSIN; VALSARTAN;

ADVERSE OUTCOME; CLINICAL EXAMINATION; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG MEGADOSE; DRUG MONITORING; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; FATIGUE; HUMAN; HYPERTENSION; INCIDENCE; LEG SWELLING; MONOTHERAPY; PATIENT INFORMATION; PATIENT MONITORING; PERIPHERAL EDEMA; PRIORITY JOURNAL; REVIEW; SOMNOLENCE; WEAKNESS; XEROSTOMIA; CHEMICALLY INDUCED DISORDER; EDEMA; RISK FACTOR;

CALCIUM CHANNEL BLOCKERS; EDEMA; HUMANS; HYPERTENSION; INCIDENCE; RISK FACTORS;

EID: 58249085089     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2008.00006.x     Document Type: Review

References (40)

1. Chan AW, Hrobjartsson A, Haahr MT, et al. Empirical evidence for selective reporting of outcomes in randomized trials: Comparison of protocols to published articles. JAMA. 2004;291(20):2457-2465.
2. Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: An evaluation of 7 medical areas. JAMA. 2001;285(4):437-443.
3. Morse MA, Califf RM, Sugarman J. Monitoring and ensuring safety during clinical research. JAMA. 2001;285(9):1201-1205.
4. Kloner RA, Weinberger M, Pool JL, et al. Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension, Comparison of Candesartan and Amlodipine for Safety, Tolerability and Efficacy (CASTLE) Study Investigators. Am J Cardiol. 2001;87(6):727-731.
5. Messerli FH. Vasodilatory edema: A common side effect of antihypertensive therapy. Curr Cardiol Rep. 2002;4(6):479-482.
6. Chrysant SG, Cohen M. Sustained blood pressure control with controlled-release isradipine. Am J Hypertens. 1995;8(1):87-89.
7. Sica DA. Pharmacotherapy review: Calcium channel blockers. J Clin Hypertens (Greenwich). 2006;8(1):53-56.
8. Fogari R, Zoppi A, Derosa G, et al. Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. J Hum Hypertens. 2007;21(3):220-224.
9. Weir MR. Incidence of pedal edema formation with dihydropyridine calcium channel blockers: Issues and practical significance. J Clin Hypertens (Greenwich). 2003;5(5):330-335.
10. Classen DC, Pestotnik SL, Evans RS, et al. Computerized surveillance of adverse drug events in hospital patients. JAMA. 1991;266(20):2847-2851.
11. Jarernsiripornkul N, Krska J, Capps PA, et al. Patient reporting of potential adverse drug reactions: A methodological study. Br J Clin Pharmacol. 2002;53(3):318-325.
12. Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men: A comparison of six antihypertensive agents with placebo. N Engl J Med. 1993;328:914-921.
13. Hermans L, Deblander A, De Keyser P, et al. At equipotent doses, isradipine is better tolerated than amlodipine in patients with mild-to-moderate hypertension: A double-blind, randomized, parallel-group study. Br J Clin Pharmacol. 1994;38(4):335-340.
14. Adalat CC. Nifedipine extended-release tablets [prescribing information]. Berlin, Germany: Bayer Schering Pharma AG; 2000.
15. Cardene SR (nicardipine hydrochloride) sustained-release capsules [prescribing information]. Nutley, NJ: Roche; 2000.
16. DynaCirc CR (isradipine) controlled-release capsules [prescribing information]. Liberty Corner, NJ: Reliant Pharmaceuticals; 2005.
17. Norvasc (amlodipine besylate) tablets [prescribing information]. New York, NY: Pfizer, Inc.; 2005.
18. Plendil (felodipine) extended-release tablets [prescribing information]. Wilmington, DE: AstraZeneca; 2003.
19. Sular (nisoldipine) extended-release tablets [prescribing information]. Atlanta, GA: Sciele Pharma, Inc.; 2003.
20. Borghi C, Prandin MG, Dormi A, et al. Improved tolerability of the dihydropyridine calcium-channel antagonist lercanidipine: The lercanidipine challenge trial. Blood Press Suppl. 2003;1:14-21.
21. Chrysant SG, Marbury TC, Robinson TD. Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension. J Hum Hypertens. 2003;17(6):425-432.
22. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial. Lancet. 2005;366(9489):895-906.
23. Frishman WH, Hainer JW, Sugg J. A factorial study of combination hypertension treatment with metoprolol succinate extended release and felodipine extended release results of the Metoprolol Succinate-Felodipine Antihypertension Combination Trial (M-FACT). Am J Hypertens. 2006;19(4):388-395.
24. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet. 2004;363(9426):2022-2031.
25. Leonetti G, Magnani B, Pessina AC, et al. Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am J Hypertens. 2002;15(11):932-940.
26. Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressurA: The CAMELOT study: a randomized controlled trial. JAMA. 2004;292(18):2217-2225.
27. Pedrinelli R, Dell'Omo G, Nuti M, et al. Heterogeneous effect of calcium antagonists on leg oedema: A comparison of amlodipine versus lercanidipine in hypertensive patients. J Hypertens. 2003;21(10):1969-1973.
28. Chrysant SG, Melino M, Karki S, et al. Combination of Olmesartan Medoxomil and Amlodipine Besylate in Controlling High Blood Pressure (COACH): A randomized, double-blind, placebo-controlled, 8-week efficacy and safety factorial study. Clin Ther. 2008;30:587-604.
29. Derry S, Kong Loke Y, Aronson JK. Incomplete evidence: The inadequacy of databases in tracing published adverse drug reactions in clinical trials. BMC Med Res Methodol. 2001;1:7.
30. Philipp T, Smith TR, Glazer R, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther. 2007;29(4):563-580.
31. Lund-Johansen P, Stranden E, Helberg S, et al. Quantification of leg oedema in postmenopausal hypertensive patients treated with lercanidipine or amlodipine. J Hypertens. 2003;21(5):1003-1010.
32. Gradman AH, Cutler NR, Davis PJ, et al. Combined enalapril and felodipine extended release (ER) for systemic hypertension. Enalapril-Felodipine ER Factorial Study Group. Am J Cardiol. 1997;79:431-435.
33. Seventh Report of the Joint National Committee on Prevention, 0 Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206-1252.
34. Chrysant SG, Bakris GL. Amlodipine/benazepril combination therapy for hypertensive patients nonresponsive to benazepril monotherapy. Am J Hypertens. 2004;17(7):590-596.
35. Epstein M, Bakris G. Newer approaches to antihypertensive therapy. Use of fixed-dose combination therapy. Arch Intern Med. 1996;156(17):1969-1978.
36. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25(6):1105-1187.
37. Messerli FH, Weir MR, Neutel JM. Combination therapy of amlodipine/ benazepril versus monotherapy of amlodipine in a practice-based setting. Am J Hypertens. 2002;15(6):550-556.
38. Messerli FH, Oparil S, Feng Z. Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension. Am J Cardiol. 2000;86(11):1182-1187.
39. Liu L, Zhang Y, Liu G, et al. The Felodipine Event Reduction (FEVER) Study: A randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens. 2005;23(12):2157-2172.
40. Altman DG, Schultz KF, Moher D, et al. The revised CONSORT statement for reporting randomized trials: Explanation and Elaboration. Ann Intern Med. 2001;134:663-694.